VIA
ONC

Vident Investment Advisory’s BeOne Medicines Ltd ONC Stock Holding History

Vident Investment Advisory’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,613
Closed -$994K – 1352
2023
Q1 		$994K Sell
4,613
-381
-8% -$91.4K 0.03% 528
2022
Q4 		$1.1M Sell
4,994
-1,230
-20% -$226K 0.04% 473
2022
Q3 		$812K Sell
6,224
-241
-4% -$41.4K 0.03% 649
2022
Q2 		$1.05M Buy
6,465
+971
+18% +$152K 0.03% 603
2022
Q1 		$1.04M Buy
5,494
+516
+10% +$110K 0.03% 684
2021
Q4 		$1.35M Sell
4,978
-1,410
-22% -$476K 0.04% 607
2021
Q3 		$2.32M Buy
6,388
+310
+5% +$101K 0.07% 329
2021
Q2 		$2.09M Sell
6,078
-3,172
-34% -$1.05M 0.06% 389
2021
Q1 		$3.22M Sell
9,250
-302
-3% -$100K 0.11% 181
2020
Q4 		$2.47M Sell
9,552
-154
-2% -$42.4K 0.1% 208
2020
Q3 		$2.78M Sell
9,706
-1,083
-10% -$255K 0.14% 127
2020
Q2 		$2.03M Sell
10,789
-962
-8% -$157K 0.11% 188
2020
Q1 		$1.45M Buy
11,751
+357
+3% +$55.8K 0.09% 274
2019
Q4 		$1.89M Sell
11,394
-2,575
-18% -$428K 0.12% 269
2019
Q3 		$1.71M Buy
13,969
+423
+3% +$56.2K 0.15% 97
2019
Q2 		$1.68M Sell
13,546
-234
-2% -$29.7K 0.14% 102
2019
Q1 		$1.82M Sell
13,780
-295
-2% -$39.8K 0.1% 310
2018
Q4 		$1.97M Sell
14,075
-1,655
-11% -$219K 0.11% 255
2018
Q3 		$2.71M Sell
15,730
-93
-0.6% -$15.6K 0.11% 267
2018
Q2 		$2.43M Sell
15,823
-3,927
-20% -$700K 0.1% 284
2018
Q1 		$3.31M Buy
19,750
+718
+4% +$97.2K 0.13% 192
2017
Q4 		$1.86M Sell
19,032
-10,159
-35% -$930K 0.08% 292
2017
Q3 		$3.02M Buy
29,191
+733
+3% +$54.6K 0.16% 137
2017
Q2 		$1.28M Sell
28,458
-1,288
-4% -$50.8K 0.11% 294
2017
Q1 		$1.09M Buy
29,746
+4,788
+19% +$174K 0.11% 302
2016
Q4 		$758K Buy
24,958
+2,207
+10% +$69.4K 0.09% 303
2016
Q3 		$701K Hold
22,751
– – 0.09% 315
2016
Q2 		$678K Buy
+22,751
New +$667K 0.1% 329

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Vident Investment Advisory's ONC Position: Q2 2023 in Review

Vident Investment Advisory sold out of BeOne Medicines Ltd (ONC) in Q2 2023, closing a stake of 4,613 shares — an estimated $994K sold.

Vident Investment Advisory first reported a position in ONC in Q2 2016 and held it in 28 quarters. The position peaked at $3.31M in Q1 2018. 208 funds tracked by Wall St. Rank hold ONC as of Q2 2023.

  • Vident Investment Advisory reported no remaining BeOne Medicines Ltd position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 4,613 BeOne Medicines Ltd shares in Q2 2023, an estimated $994K.
  • Vident Investment Advisory first reported a position in BeOne Medicines Ltd in Q2 2016 and held it in 28 quarters.
  • Vident Investment Advisory's BeOne Medicines Ltd position peaked at $3.31M in Q1 2018.
  • 208 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.